Non-Hodgkin's Lymphoma Articles | Page 3

FDA Grants Priority Review to Pembrolizumab for Relapsed/Refractory PMBCL
The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a treatment for adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Rituximab Leads to Faster Response in CLL, But PFS Not Improved
Despite a faster time to complete remission, the addition of rituximab (Rituxan) to ibrutinib (Imbruvica) did not improve PFS or overall survival OS compared with ibrutinib alone in patients with CLL. 
Acalabrutinib Highly Effective for Refractory MCL
Acalabrutinib demonstrated an objective response rate of 81% with a complete response rate of 40% for patients with refractory mantle cell lymphoma.
PD-1 Inhibitor Cemiplimab Active in B-Lymphoid Malignancies
Cemiplimab as a monotherapy and in combination with the monoclonal antibody REGN1979 demonstrated clinical activity in patients with B-cell non-Hodgkin lymphoma and Hodgkin lymphoma.
Axi-Cel Responses Sustained With Longer Follow-Up for NHL
Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma.
Tisagenlecleucel Continues to Impress in DLBCL
The CAR T-cell therapy tisagenlecleucel (Kymriah) achieved an overall response rate of 53.1% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Ibrutinib/Venetoclax Combo Impresses in Early CLL Data
The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) elicited a complete response (CR) or CR with incomplete hematologic recovery rate of 47% for patients with relapsed/refractory chronic lymphocytic leukemia.
Zanubrutinib Highly Active in Non-Hodgkin Lymphoma
The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.
Lenalidomide Plus Rituximab Safe and Effective as Initial Treatment for MCL
Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma.
Ibrutinib Combo Improves PFS in Waldenstrom Macroglobulinemia
The combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) improved progression-free survival versus rituximab alone in patients with Waldenström macroglobulinemia. 
Publication Bottom Border
Border Publication